Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990) has released an update.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has received marketing approval in China for its innovative monoclonal antibody, tagitanlimab, aimed at treating recurrent or metastatic nasopharyngeal cancer. This approval is based on a successful phase II clinical trial demonstrating a 26.5% recovery rate and a manageable safety profile. Investors are advised to exercise caution when dealing in company securities as the commercialization success of tagitanlimab is not guaranteed.
For further insights into HK:6990 stock, check out TipRanks’ Stock Analysis page.